古塞尔库马布与塞库金库马布对牛皮生物标志物的差异性药理动力学影响与长期疗效相关:一个ECLIPSE子研究
Andrew Blauvelt1, Yanqing Chen2, Patrick J Branigan3
1Blauvelt Consulting LLC, Lake Oswego, Oregon, USA.
JID innovations : skin science from molecules to population health
|September 3, 2024
概括
在牛皮患者中,Guselkumab是一种IL-23阻断剂,与secukinumab (IL-17A阻断剂) 相比,它证明了对IL-23/T辅助17通路的优越持续调节. 这提供了有关牛皮治疗耐久性的见解.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 干白素-23 (IL-23) 是一个关键的细胞因子,驱动T助手17 (Th17) 途径,在斑块性牛皮的发病过程中至关重要.
- 激活IL-23会触发细胞因子级联,这些级联将与牛皮相关的蛋白调高.
- 了解IL-23和IL-17A阻塞之间的差异对于牛皮治疗的有效性和耐用性至关重要.
研究的目的:
- 为了研究IL-23和IL-17A阻塞在斑块性牛皮的机制差异.
- 确定可预测对guselkumab和secukinumab的药理学反应的生物标志物.
- 探索这些差异对临床反应耐久性的影响.
主要方法:
- 分析了用guselkumab或secukinumab治疗的牛皮患者的血清和皮肤活检.
- 评估了IL-17F和IL-22作为药理动力学生物标志物的血清水平.
- 利用患者样本的蛋白质学和转录学分析来评估路径调节.
主要成果:
- 与24周和48周的secukinumab相比,guselkumab治疗导致血清IL-17F和IL-22水平显著降低.
- 对IL-23/Th17通路的持续调节被观察到与guselkumab.
- 基摩卡因,TNF和免疫信号通路的差异调节在guselkumab时更为明显.
结论:
- 古塞尔库马布在牛皮中提供了比secukinumab更持久的IL-23/Th17通路调节.
- 通过IL-23与IL-17A阻断的差异性途径调制影响了牛皮治疗结果.
- 这些发现对优化牛皮治疗策略和了解反应耐久性有影响.
相关概念视频
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
01:03Pharmacodynamic Responses: Different Types
Pharmacodynamics is the scientific study of a drug's biochemical or physiological influence on the body. It categorizes responses into continuous, discrete (or categorical), and time-to-event outcomes. Continuous responses yield numerical values within a certain range, such as blood pressure readings and blood glucose levels, gauging the efficacy of antihypertensive and antidiabetic drugs. Discrete responses can be binary, indicating whether a drug has an effect or not, or ordinal, exemplifying...